Logo do repositório
 
Publicação

Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis

2019-07-08Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorTorre, Carla
dc.contributor.authorGuerreiro, José
dc.contributor.authorMendes, Zilda
dc.contributor.authorMiranda, Ana
dc.contributor.authorBragança, Fátima
dc.contributor.authorCristino, Joaquim
dc.contributor.authorCanhão, Helena
dc.contributor.authorCanhão, Helena
dc.contributor.authorBranco, Jaime
dc.contributor.authorBranco, Jaime
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentro de Estudos de Doenças Crónicas (CEDOC)
dc.contributor.institutionEscola Nacional de Saúde Pública (ENSP)
dc.contributor.pblSociedade Portuguesa de Reumatologia
dc.date.accessioned2019-09-16T22:43:02Z
dc.date.available2019-09-16T22:43:02Z
dc.date.issued2019-07-08
dc.description.abstractBACKGROUND: Osteoporotic fractures are a major cause of morbidity and mortality. It is recognized that persistence with medication is crucial to reach optimal clinical outcomes. We aimed to estimate the persistence level to weekly and monthly oral bisphosphonates (OBP) in women with postmenopausal osteoporosis (PMO) over 24 months from therapy initiation in a population-based setting. METHODS: Prospective observational cohort study of PMO women ≥50 years initiating OBP recruited through community pharmacies. Data were collected at baseline during face-to-face interviews. Follow-up included pharmacy records (refill dates and medication possession; cohort 1) and telephone-surveys for patients who agreed to be interviewed (cohort 2). Patients were classified as persistent if they refilled their prescription within 30 days after exhausting the time covered by their previous supply. Log-rank tests were used to compare Kaplan-Meier curves of time to non-persistence. RESULTS: Of 427 women recruited with a mean age of 65.0 years, 380 (89%) agreed to be interviewed (cohort 2). Over 24-months of follow-up, 3.4% (95% CI: [2.0%; 5.6%]) of all subjects were persistent to OBP based on pharmacy records. Analysis combining both self-reported information and pharmacy records (cohort 2) showed a persistence estimate of 20.0% (95% CI: [16.1%; 24.2%]). Lower persistence was associated with more frequent OBP dosing and living alone. The most common reason for treatment discontinuation was self-reported adverse events (27.6%). CONCLUSIONS: Results indicate a low level of persistence with OBP. Barriers and reasons leading to discontinuation of anti-PMO therapies should be proactively addressed to promote persistence and improve fracture protection.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent12
dc.format.extent985411
dc.identifier.issn0303-464X
dc.identifier.otherPURE: 14633840
dc.identifier.otherPURE UUID: c732a266-01ef-4b87-b8f0-2d15c084ec15
dc.identifier.otherPubMed: 31280276
dc.identifier.otherORCID: /0000-0003-1894-4870/work/67178337
dc.identifier.otherWOS: 000478729600003
dc.identifier.otherScopus: 85071786250
dc.identifier.urihttp://www.actareumatologica.pt/archive_detail.php?id=226
dc.identifier.urlhttp://www.actareumatologica.pt/archive_detail.php?id=226
dc.language.isoeng
dc.peerreviewedyes
dc.titleLow persistence with oral biphosphonate treatment in postmenopausal osteoporosisen
dc.typejournal article
degois.publication.firstPage114
degois.publication.issue2
degois.publication.lastPage125
degois.publication.titleActa Reumatológica Portuguesa
degois.publication.volume44
dspace.entity.typePublication
person.familyNameCanhão
person.familyNameBranco
person.givenNameHelena
person.givenNameJaime
person.identifier379800
person.identifier.ciencia-id5A17-C6D9-DBC8
person.identifier.ciencia-idB612-E5C3-60DC
person.identifier.orcid0000-0003-1894-4870
person.identifier.orcid0000-0001-7024-4375
person.identifier.ridC-9611-2018
person.identifier.scopus-author-id6602393492
person.identifier.scopus-author-id8417815400
rcaap.rightsopenAccess
relation.isAuthorOfPublicationc87f58c0-b53d-4321-9bd7-39554e6001b5
relation.isAuthorOfPublication4caea9f3-40dd-4c95-98ec-0120509287c0
relation.isAuthorOfPublication.latestForDiscovery4caea9f3-40dd-4c95-98ec-0120509287c0

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1253_low_persistence_with_oral_biphosphonate_treatment_in_postmenopausal_osteoporosis_file.pdf
Tamanho:
962.32 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: CEDOC - Artigos em revista nacional com arbitragem científica